Cardiovascular effects of sibutramine in the treatment of obese adolescents: Results of a randomized, double-blind, placebo-controlled study

Pediatrics

Volumn 120, Issue 1, 2007, Pages

  Daniels, Stephen R ^a,i   Long, Barbara ^b   Crow, Scott ^c   Styne, Dennis ^d   Sothern, Melinda ^e   Vargas Rodriguez, Ileana ^f   Harris, Lisa ^g   Walch, Julia ^h   Jasinsky, Olga ^h   Cwik, Kristine ^h   Hewkin, Ann ^h   Blakesley, Vicky ^h  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f The Comprehensive Weight Control Program   (United States)

^g Chase Wellness Center   (United States)

^h ABBOTT LABORATORIES   (United States)

ⁱ Nutrition Obesity Research Center at the University of Colorado   (United States)

Author keywords

Adolescents; Blood pressure; Obesity; Sibutramine; Weight loss

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADOLESCENT; ARTICLE; BEHAVIOR THERAPY; BODY MASS; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

EID: 34447126288     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2137     Document Type: Article

References (40)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39-47
2. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents and adults, 1999-2002. JAMA. 2004;291:2847-2850
3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898-918
4. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH publication 98-4083. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998
5. Lobstein T, Baur L, Uauy R; IASO International Obesity Task Force. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5(suppl 1):S4-S104
6. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000;105:671-680
7. Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics. 1998;102(3). Available at: www.pediatrics.org/cgi/content/ full/102/3/e29
8. Friberg P, Allansdotter-Johnsson A, Ambring A, et al. Increased left ventricular mass in obese adolescents. Eur Heart J. 2004;25:987-992
9. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
10. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA. 1990;264:2519-2523
11. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol. 1994;13:373-383
12. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord. 1999;23(suppl 2):S2-S11.
13. Wilson P, O'Meara S, Summerbell C, Kelly S; Effective Health Care Review Team. The prevention and treatment of childhood obesity. Qual Saf Health Care. 2003;12:65-74
14. Xenical (orlistat) [US product information]. Nutley, NJ: Roche Pharmaceuticals; 2007
15. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198
16. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125
17. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-184
18. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord. 2002;26(suppl 4):S38-S41.
19. Jordan J, Scholze J, Matiba B, Wirth W, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord. 2005;29:509-516
20. Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Int Med. 2006;145:81-90
21. Rosner B, Prineas R, Loggie J, Daniels S. Percentiles for body mass index in U.S. children 5 to 17 years of age. J Pediatr. 1998;132:211-222
22. Meridia (sibutramine hydrochloride) [package insert]. North Chicago, IL: Abbott Laboratories; 2006
23. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576
24. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805-1812
25. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90:1460-1465
26. García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled parallel group trial. Clin Therap. 2006;28:770-782
27. Sorof JM, Poffenbarger T, Franco K, Bernard L, Portman RJ. Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr. 2002;140:660-666
28. Lurbe E, Thijs L, Redon J, Alvarez V, Tacons J, Staessen J. Diurnal blood pressure curve in children and adolescents. J Hypertens. 1996;14:41-46
29. Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006;79:500-508
30. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992;327:1350-1355
31. Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey Smith G. Childhood obesity and adult cardiovascular mortality: a 57-y follow-up study based on the Boyd Orr cohort. Am J Clin Nutr. 1998;67:1111-1118
32. Nieto FJ, Szklo M, Comstock GW. Childhood weight and growth rate as predictors of adult mortality. Am J Epidemiol. 1992;136:201-213
33. Srinivasan SR, Bao W, Wattigney WA, Berenson GS. Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study. Metabolism. 1996;45:235-240
34. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103:1175-1182
35. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656
36. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157:821-827
37. Yanovski JA, Yanovski SZ. Treatment of pediatric and adolescent obesity. JAMA. 2003;289:1851-1853
38. National Heart, Lung, and Blood Institute, Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health [published correction appears in Obes Res. 1998;6:464]. Obes Res. 1998;6(suppl 2):51S-209S
39. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350
40. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995;141:1128-1141